Ipilimumab vs Von Willebrand Factor Human
Ipilimumab vs Von Willebrand Factor Human: Overview
This comparison examines the pharmacological differences between Ipilimumab and Von Willebrand Factor Human.
Mechanism of Action
Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.
Pharmacokinetics
Half-life: Ipilimumab — 14.7 days.
Chemical Properties
Type: Ipilimumab — Antibody; Von Willebrand Factor Human — Unknown.